NCT00563680View on ClinicalTrials.gov

QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2012

Conditions
Askin's TumorsDesmoplastic Small Round Cell TumorsEstraosseous Ewing's TumorEwing's Family TumorEwing's SarcomaPrimitive Neuroectodermal Tumors (PNETs)Sarcoma
Interventions
DRUG

AMG 479

AMG 479 is a fully human monoclonal antibody (IgG1) against the insulin-like growth factor receptor-1 (IGF-1R). IGF-1R signaling has been shown to play a critical role in the survival of cancer cells. AMG 479 inhibits the binding of both IGF-1 and IGF-2 to IGF-1R, thus inhibiting ligand-dependent receptor activation. Inhibition of IGF-1R signaling with AMG 479 provides a potential mechanism for inhibiting tumor growth and survival.

Sponsors

Lead Sponsor

NantCell, Inc.
All Listed Sponsors
lead

NantCell, Inc.

INDUSTRY

NCT00563680 - QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors | Biotech Hunter | Biotech Hunter